Bronchitis, Chronic
Conditions
Keywords
Acute Exacerbation of Chronic Bronchitis (AECB) patients
Brief summary
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events. This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.
Interventions
Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients at least 35 years of age with a diagnosis of Acute Exacerbation of Chronic Bronchitis (AECB) and decision taken by the investigator to treat with Avelox.
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time until improvement of acute exacerbation | End of study |
Secondary
| Measure | Time frame |
|---|---|
| Time until cure of acute exacerbation | End of study |
| Severity of AECB according to Antonisen criteria | Baseline |
| Impact of AECB on daily life activities | Baseline |
| Safety of Avelox under daily life treatment conditions | Throughout treatment |
Countries
Albania, Bosnia and Herzegovina, Kazakhstan, Moldova, North Macedonia, Russia, Slovakia, Ukraine
Outcome results
None listed